Biocon Biologics Partners with Janssen to Launch Biosimilar for Autoimmune Diseases

Biocon Biologics has partnered with Janssen to introduce a biosimilar medication for treating autoimmune diseases in multiple countries. The agreement resolves patent disputes, enabling market entries and regulatory filings. Bmab 1200 will bolster Biocon's immunology segment, offering affordable treatments for conditions like psoriasis and Crohn's disease.

Biocon Biologics, a subsidiary of Biocon Ltd, announced on Thursday that it has signed an agreement with Janssen to launch a biosimilar drug aimed at treating autoimmune diseases in Europe, the United Kingdom, Canada, and Japan.

Under the deal, which also involves Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson, Biocon Biologics will commercialize Bmab 1200, a proposed biosimilar to Stelara. This settlement resolves existing patent disputes and establishes market entry dates in the specified regions.

According to statements from the company, regulatory reviews in these markets are ongoing. Biocon Biologics also previously announced a US settlement for the Bmab 1200, with expected market entry no later than February 22, 2025, pending USFDA approval. CEO & Managing Director Shreehas Tambe highlighted this agreement as a significant milestone in offering an affordable and effective treatment for autoimmune diseases.

(With inputs from agencies.)